comparison of glp-1 integrated weight management platforms Market Overview: Agonists and the Obesity Market | Blog GLP-1 agonists and changes in

Cardio renal metabolic complication-based pharmacotherapy Atheerotic cardiovascular disease (ASCVD) and heart failure (HF)roscl Cardiovascular disease remains the leading cause of death in people with obesity, even in the absence of diabetes

GLP-1 agonists are a class of medications most commonly used to help manage blood sugar levels in patients with Type 2 diabetes

Management options may include lifestyle modifications, treatment of underlying cardiovascular disease, psychological support, or specific ED therapies such as phosphodiesterase-5 inhibitors (e.g., sildenafil), which can be safely used alongside tirzepatide in most patients following cardiovascular assessment

Thus, GLPs and dipeptidyl peptidase IV (DPP-IV) inhibitors have recently gained attention in IBD research

And its doing a fantastic job in that arena by improving glycemic control, but doctors have expanded its use to address weight loss, for good reason